Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Columbia Laboratories, Inc. today reported financial results of the three- and twelve-months periods ended December 31, 2009.

11 Mar 2010

QLT announces results from Phase II clinical trials and device study for PPDS

QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.

11 Mar 2010

Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program

Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA.

10 Mar 2010

Roche, OrbiMed, McKinsey announce fifteen finalists of SEED Competition

Roche, OrbiMed, and McKinsey announced fifteen finalists of the SEED Competition at the SEED Finalist Coaching Day event in Shanghai’s Zhangjiang Hi-Tech Park on March 2, 2010. The event was managed and presented by ChinaBio® Accelerator. The finalists will go on to compete for the grand prize of RMB 300,000 to be presented at the SEED Final Competition and Award Ceremony in Shanghai on April 23, 2010.

6 Mar 2010

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

4 Mar 2010

University of Calgary chemist finds potential tool to measure impact of nanoparticles on human health

University of Calgary chemistry professor David Cramb is a step closer to helping solve a complex problem in nanotechnology: the impact nanoparticles have on human health and the environment.

4 Mar 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive top-line results reported in December 2009 by pSivida and its licensee, Alimera Sciences, Inc.

4 Mar 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

European Journal of Drug Metabolism and Pharmacokinetics to be published by Springer

Starting in 2010, Springer will publish the European Journal of Drug Metabolism and Pharmacokinetics. All aspects of drug delivery and bioavailability are covered in the journal, which was previously published by the Swiss publisher M-decine & Hygi-ne. The journal was founded in 1975 by the late Professor Achille Benakis at the University of Geneva, Switzerland, and through the years gathered a loyal community of authors and readers.

3 Mar 2010

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Unilife Corporation, today announced that it has agreed to a list of therapeutic drug classes ("Exclusivity List") within which sanofi-aventis has the exclusive right to purchase the Unifill™ ready-to-fill syringe.

3 Mar 2010

Drug Delivery News and Research

Further Reading

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

StockPreacher.com announces investment report featuring Generex Biotechnology

BeaconEquity.com announces investment report featuring NexMed

Development of promising new cancer therapies: OICR announces $1M investment

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

QLT announces results from Phase II clinical trials and device study for PPDS

Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program

Roche, OrbiMed, McKinsey announce fifteen finalists of SEED Competition

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

University of Calgary chemist finds potential tool to measure impact of nanoparticles on human health

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

European Journal of Drug Metabolism and Pharmacokinetics to be published by Springer

Unilife agrees to Exclusivity List; Sanofi-aventis secures exclusivity for Unifill syringe

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News